438 related articles for article (PubMed ID: 27438183)
1. Levetiracetam and Valproate Retention Rate in Juvenile Myoclonic Epilepsy.
Sala-Padró J; Toledo M; Santamarina E; González-Cuevas M; Raspall-Chaure M; Sueiras-Gil M; Quintana M; Salas-Puig X
Clin Neuropharmacol; 2016; 39(6):299-301. PubMed ID: 27438183
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.
Chowdhury A; Brodie MJ
Epilepsy Res; 2016 Jan; 119():62-6. PubMed ID: 26675554
[TBL] [Abstract][Full Text] [Related]
3. Levetiracetam in genetic generalized epilepsy: A prospective unblinded active-controlled trial.
Tabrizi N; Zarvani A; Rezaei P; Cheraghmakani H; Alizadeh-Navaei R
Epilepsy Res; 2019 Nov; 157():106214. PubMed ID: 31627041
[TBL] [Abstract][Full Text] [Related]
4. Response to levetiracetam or lamotrigine in subjects with Juvenile Myoclonic Epilepsy previously treated with valproic acid: A single center retrospective study.
Milano C; Turco F; Pizzanelli C; Bonanni E; Siciliano G; Fornai F; Giorgi FS
Epilepsy Behav; 2021 Feb; 115():107706. PubMed ID: 33423017
[TBL] [Abstract][Full Text] [Related]
5. Levetiracetam monotherapy in juvenile myoclonic epilepsy.
Sharpe DV; Patel AD; Abou-Khalil B; Fenichel GM
Seizure; 2008 Jan; 17(1):64-8. PubMed ID: 17692537
[TBL] [Abstract][Full Text] [Related]
6. Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020.
Kılıç B; Serdaroğlu E; Polat BG; İnce T; Esenülkü G; Topçu Y; Serdaroğlu A; Haspolat Ş; Tekgül H; Okuyaz Ç; Cansu A; Aydın K
Seizure; 2022 Jul; 99():48-53. PubMed ID: 35594744
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy.
Kothare SV; Valencia I; Khurana DS; Hardison H; Melvin JJ; Legido A
Epileptic Disord; 2004 Dec; 6(4):267-70. PubMed ID: 15634623
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of low-dose valproic acid treatment in patients with juvenile myoclonic epilepsy.
Gürer R; Aydın Ş; Özkara Ç
Seizure; 2019 Aug; 70():43-48. PubMed ID: 31252363
[TBL] [Abstract][Full Text] [Related]
9. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.
Trinka E; Marson AG; Van Paesschen W; Kälviäinen R; Marovac J; Duncan B; Buyle S; Hallström Y; Hon P; Muscas GC; Newton M; Meencke HJ; Smith PE; Pohlmann-Eden B;
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1138-47. PubMed ID: 22933814
[TBL] [Abstract][Full Text] [Related]
10. Electroclinical aspects and therapy of Han patients with juvenile myoclonic epilepsy in northern China.
Wang L; Jiang Z; Chen BB; Wang CT; Wang JX; Bai J; Wang B; Jin L; Zhang WJ; Deng YC; Zhao G; Dang JX; Wang D; Jia SS; Wang TC; Jia FY; Zhang L; Liu YH
Epilepsy Behav; 2016 Sep; 62():204-8. PubMed ID: 27494356
[TBL] [Abstract][Full Text] [Related]
11. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Kerkhof M; Dielemans JC; van Breemen MS; Zwinkels H; Walchenbach R; Taphoorn MJ; Vecht CJ
Neuro Oncol; 2013 Jul; 15(7):961-7. PubMed ID: 23680820
[TBL] [Abstract][Full Text] [Related]
12. Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats.
van Vliet EA; Edelbroek PM; Gorter JA
Epilepsia; 2010 Mar; 51(3):362-70. PubMed ID: 19674045
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and therapeutic approach to drug-resistant juvenile myoclonic epilepsy.
Ascoli M; Mastroianni G; Gasparini S; Striano P; Cianci V; Neri S; Bova V; Mammì A; Gambardella A; Labate A; Aguglia U; Ferlazzo E
Expert Rev Neurother; 2021 Nov; 21(11):1265-1273. PubMed ID: 33993822
[TBL] [Abstract][Full Text] [Related]
14. Initial levetiracetam versus valproate monotherapy in antiseizure medicine (ASM)-naïve pediatric patients with idiopathic generalized epilepsy with tonic-clonic seizures.
Abdelmesih SK; Elkhateeb N; Zakaria M; Girgis MY
Seizure; 2021 Oct; 91():263-270. PubMed ID: 34246881
[TBL] [Abstract][Full Text] [Related]
15. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate.
Calleja S; Salas-Puig J; Ribacoba R; Lahoz CH
Seizure; 2001 Sep; 10(6):424-7. PubMed ID: 11700996
[TBL] [Abstract][Full Text] [Related]
16. [Juvenile myoclonic epilepsy with recurrent myoclonic status: efficacy of valproate].
Crespel A; Velizarova R; Genton P; Gélisse P
Therapie; 2009; 64(5):321-3. PubMed ID: 19863907
[TBL] [Abstract][Full Text] [Related]
17. Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents.
Verrotti A; Cerminara C; Coppola G; Franzoni E; Parisi P; Iannetti P; Aloisi P; Tozzi E; Cusmai R; Vigevano F; Chiarelli F; Curatolo P
Dev Med Child Neurol; 2008 Jan; 50(1):29-32. PubMed ID: 18173626
[TBL] [Abstract][Full Text] [Related]
18. [Juvenile myoclonic epilepsy].
Syvertsen MR; Markhus R; Selmer KK; Nakken KO
Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1610-3. PubMed ID: 22875125
[TBL] [Abstract][Full Text] [Related]
19. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs).
Stepanova D; Beran RG
Seizure; 2014 May; 23(5):371-6. PubMed ID: 24630809
[TBL] [Abstract][Full Text] [Related]
20. Treatment of juvenile myoclonic epilepsy.
Auvin S
CNS Neurosci Ther; 2008; 14(3):227-33. PubMed ID: 18684236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
